Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
14.70
+1.52 (11.53%)
At close: Nov 6, 2025, 4:00 PM EST
14.70
0.00 (0.00%)
After-hours: Nov 6, 2025, 4:10 PM EST
Pharming Group Revenue
Pharming Group had revenue of $97.29M in the quarter ending September 30, 2025, with 29.98% growth. This brings the company's revenue in the last twelve months to $362.27M, up 26.78% year-over-year. In the year 2024, Pharming Group had annual revenue of $297.20M with 21.15% growth.
Revenue (ttm)
$362.27M
Revenue Growth
+26.78%
P/S Ratio
2.39
Revenue / Employee
$896,718
Employees
404
Market Cap
865.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 297.20M | 51.88M | 21.15% |
| Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
| Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
| Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
| Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
PHAR News
- 3 hours ago - Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 14 days ago - Pharming Group to report third quarter 2025 financial results and provide business update on November 6 - GlobeNewsWire
- 17 days ago - Pharming Group announces presentations at 2025 ACAAI Annual Scientific Meeting showcasing new data across rare disease portfolio - GlobeNewsWire
- 4 weeks ago - Pharming Group provides update on previously announced G&A expense reduction plan - GlobeNewsWire
- 5 weeks ago - Pharming Group announces U.S. FDA acceptance and Priority Review of supplemental New Drug Application for leniolisib in children with APDS aged 4 to 11 years - GlobeNewsWire
- 2 months ago - Pharming Group promoted to the Euronext AMX® index - GlobeNewsWire
- 2 months ago - Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire